
BioStem Technologies (($BSEM)) has held its Q3 earnings call. Read on for the main highlights of the call. BioStem Technologies’ earnings call struck a cautiously optimistic tone, highlighting hospital growth,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BSEM | BioStem Technologies | 0.64 | -3.33 | -83.98% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.64 | -83.98% |

BioStem Technologies (($BSEM)) has held its Q3 earnings call. Read on for the main highlights of the call. BioStem Technologies’ earnings call struck a cautiously optimistic tone, highlighting hospital growth,

BioStem Technologies (BSEM) is scheduled to report 3rd quarter earnings on 11/12/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect BioStem Technologies to post earnings of -$0.43

BioStem Technologies ($BSEM) announced an update on their ongoing clinical study. Study Overview: BioStem Technologies (BSEM) updated its study, officially titled “A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Venous

BioStem Technologies (BSEM) announced its chair and CEO, Jason Matuszewski, and COO, Andrew Van Vurst, each exercised a portion of their outstanding options to purchase 250,000 shares of BioStem common

This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.22M shares of common stock. The company is not selling any

BioStem Technologies (BSEM) announced that the United States Patent and Trademark Office, USPTO, has issued one patent and three notices of allowance for additional patent applications and the Mexican Institute

BioStem Technologies ( ($BSEM) ) has provided an update. On September 29–30, 2026, BioStem Technologies raised approximately $3 million in a private placement, selling 735,296 shares of common stock at

BioStem Technologies (BSEM) announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of the company’s common stock, Series A warrants to purchase up

This filing relates to the offer and sale from time to time by the selling stockholders of up to 12.05M shares of common stock. The company is not selling any

BioStem Technologies ( ($BSEM) ) has provided an announcement. On September 18, 2026, BioStem Technologies entered into a $40 million committed equity facility with Roth Principal Investments, giving the company
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Aug 24, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 5, 2027TBA | $13.57M | $-0.45 | $7.53M | 0.08 | -0.30 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.